RU2657750C1 - Новые способы направленного воздействия на раковые стволовые клетки - Google Patents

Новые способы направленного воздействия на раковые стволовые клетки Download PDF

Info

Publication number
RU2657750C1
RU2657750C1 RU2016123004A RU2016123004A RU2657750C1 RU 2657750 C1 RU2657750 C1 RU 2657750C1 RU 2016123004 A RU2016123004 A RU 2016123004A RU 2016123004 A RU2016123004 A RU 2016123004A RU 2657750 C1 RU2657750 C1 RU 2657750C1
Authority
RU
Russia
Prior art keywords
compound
cancer
polymorph
degrees
peak
Prior art date
Application number
RU2016123004A
Other languages
English (en)
Russian (ru)
Inventor
Чиан Цзя ЛИ
Дэвид ЛЕДЖЕТТ
Ючжи ЛИ
Вэй Ли
Original Assignee
Бостон Байомедикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бостон Байомедикал, Инк. filed Critical Бостон Байомедикал, Инк.
Application granted granted Critical
Publication of RU2657750C1 publication Critical patent/RU2657750C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
RU2016123004A 2010-03-19 2011-03-21 Новые способы направленного воздействия на раковые стволовые клетки RU2657750C1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31588610P 2010-03-19 2010-03-19
US31589010P 2010-03-19 2010-03-19
US61/315,890 2010-03-19
US61/315,886 2010-03-19
US32581410P 2010-04-19 2010-04-19
US61/325,814 2010-04-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2012144420/15A Division RU2591823C2 (ru) 2010-03-19 2011-03-21 Новые способы направленного воздействия на раковые стволовые клетки

Publications (1)

Publication Number Publication Date
RU2657750C1 true RU2657750C1 (ru) 2018-06-15

Family

ID=50940329

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016123004A RU2657750C1 (ru) 2010-03-19 2011-03-21 Новые способы направленного воздействия на раковые стволовые клетки
RU2015142279A RU2015142279A (ru) 2010-03-19 2011-03-21 Новые соединения и композиции для нацеливания на злокачественные стволовые клетки

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015142279A RU2015142279A (ru) 2010-03-19 2011-03-21 Новые соединения и композиции для нацеливания на злокачественные стволовые клетки

Country Status (11)

Country Link
EP (2) EP3295796A1 (enExample)
JP (11) JP5993390B2 (enExample)
CN (3) CN104016951B (enExample)
CA (3) CA2993363A1 (enExample)
DK (1) DK3108750T3 (enExample)
ES (1) ES2689928T3 (enExample)
HU (1) HUE066482T2 (enExample)
NZ (2) NZ701237A (enExample)
PT (1) PT2547205T (enExample)
RU (2) RU2657750C1 (enExample)
SG (3) SG10201502079VA (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
CN104016951B (zh) * 2010-03-19 2016-07-13 北京强新生物科技有限公司 靶向癌症干细胞的化合物和组合物
DK2547205T3 (da) * 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2016196935A1 (en) * 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
JP6751658B2 (ja) 2016-11-15 2020-09-09 クラリオン株式会社 音声認識装置、音声認識システム
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
KR20240012436A (ko) * 2021-05-25 2024-01-29 액티브 바이오테크 에이비 복수의 타스퀴니모드 입자 및 그 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20070060521A1 (en) * 1999-01-27 2007-03-15 The University Of South Florida, A Public Corporation Of The State Of Florida Corporation Inhibition of STAT3 signal transduction for human cancer therapy
RU2350606C2 (ru) * 2002-11-15 2009-03-27 Вертекс Фармасьютикалз Инкорпорейтед Диаминотриазолы, пригодные в качестве ингибиторов протеинкиназ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
EP0945131A1 (de) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Perorale Wirkstoff-Suspension
WO2004026253A2 (en) * 2002-09-17 2004-04-01 Arqule, Inc. Novel lapacho compounds and methods of use thereof
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
TW200803854A (en) * 2005-09-30 2008-01-16 Smithkline Beecham Corp Pharmaceutical compositions
EP1860126A1 (en) * 2006-05-26 2007-11-28 INEOS Manufacturing Belgium NV Polyolefin powder
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
KR20110031370A (ko) * 2008-07-08 2011-03-25 베타 파마, 인크. 염산 ｉｃｏｔｉｎｉｂ, 합성, 결정형, 약학적 조성물 및 이의 사용
NZ602328A (en) * 2010-03-19 2014-11-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
DK2547205T3 (da) * 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
CN104016951B (zh) * 2010-03-19 2016-07-13 北京强新生物科技有限公司 靶向癌症干细胞的化合物和组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060521A1 (en) * 1999-01-27 2007-03-15 The University Of South Florida, A Public Corporation Of The State Of Florida Corporation Inhibition of STAT3 signal transduction for human cancer therapy
RU2350606C2 (ru) * 2002-11-15 2009-03-27 Вертекс Фармасьютикалз Инкорпорейтед Диаминотриазолы, пригодные в качестве ингибиторов протеинкиназ
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VENEGAS W. et al. Relationship between the chemical structure and the mutagenic and carcinogenic potentials of five naphthofurans. Cancer res. 1984 May;44(5):1969-75, , найдено 23.10.2017 из PubMed PMID:6713395. *
VENEGAS W. et al. Relationship between the chemical structure and the mutagenic and carcinogenic potentials of five naphthofurans. Cancer res. 1984 May;44(5):1969-75, реферат, найдено 23.10.2017 из PubMed PMID:6713395. *

Also Published As

Publication number Publication date
EP3108750B1 (en) 2018-07-04
HUE066482T2 (hu) 2024-08-28
PT2547205T (pt) 2024-05-27
CN107311969B (zh) 2022-01-28
RU2015142279A3 (enExample) 2019-02-26
SG10201502079VA (en) 2015-06-29
JP2014098050A (ja) 2014-05-29
JP5993390B2 (ja) 2016-09-14
JP2014098048A (ja) 2014-05-29
CN107311969A (zh) 2017-11-03
EP3295796A1 (en) 2018-03-21
JP2018115209A (ja) 2018-07-26
JP2020063308A (ja) 2020-04-23
CA2993363A1 (en) 2011-09-22
JP2022020002A (ja) 2022-01-27
CA2959951A1 (en) 2011-09-22
CA2959931A1 (en) 2011-09-22
JP2014098049A (ja) 2014-05-29
SG10201704745UA (en) 2017-07-28
CN106860443A (zh) 2017-06-20
JP2020114888A (ja) 2020-07-30
RU2015142279A (ru) 2018-12-28
JP2016222723A (ja) 2016-12-28
JP2015232037A (ja) 2015-12-24
JP6246169B2 (ja) 2017-12-13
NZ712826A (en) 2017-03-31
SG10201706265PA (en) 2017-08-30
ES2689928T3 (es) 2018-11-16
CN104016951A (zh) 2014-09-03
CN104016951B (zh) 2016-07-13
JP2015098489A (ja) 2015-05-28
JP2018002744A (ja) 2018-01-11
DK3108750T3 (en) 2018-10-22
NZ701237A (en) 2016-04-29
EP3108750A1 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
RU2591823C2 (ru) Новые способы направленного воздействия на раковые стволовые клетки
RU2571661C2 (ru) Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
CN106211758B (zh) 2-乙酰基萘并[2,3-b]呋喃-4,9-二酮用于治疗癌症的用途
CN107311969B (zh) 靶向癌症干细胞的新的化合物和组合物
AU2015218436B2 (en) Novel Methods For Targeting Cancer Stem Cells
HK1239527A1 (en) Novel compounds and compositions for targeting cancer stem cells
HK1229744A1 (en) 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
HK1179478A (en) Novel methods for targeting cancer stem cells
HK1179478B (en) Novel methods for targeting cancer stem cells
HK1179535A (en) Novel compounds and compositions for targeting cancer stem cells
HK1179535B (en) Novel compounds and compositions for targeting cancer stem cells